Former Aetna Chairman and CEO Mark Bertolini says investors currently are trading "on a basis that says, 'does this drug work today? Did this trial pass today?''"
The U.S. economy could be slowing down, but RDM Financial Group's Ron Weiner has three sector picks that could weather any trouble ahead.
Eisai said it has begun phase 3 clinical trials of Alzheimer's treatment, a day after the Japanese drugmaker and U.S. partner Biogen scrapped trials for its own Alzheimer's drug.
Jared Holz, healthcare strategist at Jefferies, and Paul Matteis, co-head of biotech research at Stifel, discuss Biogen after shares of the company plunged on Thursday.
*Fed sees no rate hikes in 2019, financials fall. *Apple boosts tech stocks; Micron leads gains in chipmakers. March 21- Technology shares pushed Wall Street's main indexes higher on Thursday, offseting losses in U.S. lenders after the Federal Reserve decided not to raise interest rates this year.
*Fed sees no rate hikes in 2019. March 21- U.S. stocks eked out gains on Thursday as declines in financial stocks after the Federal Reserve's move to not raise interest rates this year were countered by gains in technology companies. "The fear factor here is how weak exactly is the economy and how afraid is the Fed at this point, because to make a 180 degree turn like they...
PolarityTE said the SEC subpoenaed it earlier this month for documents related to any promotion of the company or its securities, among other items.
Start-up fertility establishments are a popular alternative to traditional fertility clinics — so much so that Wall Street is taking notice. But some physicians say they're concerned clients may not get all of the information they need.
The IBB, an ETF that tracks biotech's biggest players, was down more than 2 percent Wednesday, on pace for its worst day since Feb. 7, when it lost 2.5 percent.
CNBC's "Power Lunch" team discusses potential biotech buys focused on gene therapy with Andrew Bary, associate editor of Barron's.
Ben Johnson of Morningstar and Dave Nadig of ETF.com join 'ETF Edge' to discuss how they're playing biotech ETFs.
Craig Johnson of Piper Jaffray and John Petrides of Point View Wealth Management discuss why investors can trust the biotech rally with CNBC's Mike Santoli.
Livongo Executive Chairman Glen Tullman joins "Squawk Alley" to discuss the company's new partnership with tech giant Amazon to create a voice-controlled blood pressure monitor.
CNBC's "Power Lunch" is joined by Horizon Pharma CEO Timothy Walbert to talk about the positive trial for a new eye drug and the company's outlook.
The activist investor says it intends to use its stake in Bristol-Myers Squibb to oppose its acquisition of Celgene.
CNBC's "Power Lunch" team discusses whether there's more biotech buyouts ahead with Michael Yee of Jefferies.
Roche CEO Severin Schwan says acquiring Spark is an expression of the company's commitment to treating hemophilia.
Roche is buying U.S.-based gene therapy specialist Spark Therapeutics for $4.3 billion after developments in this area convinced the Swiss drugmaker to "step up"
Swiss drugmaker Roche Holding AG is nearing a deal to acquire U.S. biotechnology company Spark Therapeutics Inc, the Wall Street Journal reported on Saturday, citing people familiar with the matter.
Despite competition from other drugmakers, Pfizer has been able to maintain a significant share in the erectile dysfunction market thanks in part to launching its own generic version of the blue, diamond-shaped pill.